CureVac N.V. (CVAC)
|52 Week Range||5.63-20.45|
|1y Target Est||-|
|DCF Unlevered||CVAC DCF ->|
|DCF Levered||CVAC LDCF ->|
|Debt / Equity||45.68%||Neutral|
Upgrades & Downgrades
Latest CVAC news
UBS: CureVac has a ‘potentially competitive mRNA platform'
19 January 2023
CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities a...
UBS reveals a biotech stock that can nearly double from here
19 January 2023
Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.
7 Biotech Stocks That Will Make You Rich in 10 Years
18 January 2023
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r...
Why CureVac's Shares Jumped on Tuesday
10 January 2023
The stock rose for the third consecutive day.
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of g...
9 January 2023
A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.
CureVac shares surge after preliminary data on COVID-19 and flu shots
9 January 2023
CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to adva...
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
6 January 2023
Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clin...
CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript
16 November 2022
Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC ) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - C...
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on...
10 November 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonu...
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >